Scarica l'app Stockscreener
409.94
0.60%
2.0363
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$407.90
Aprire:
$409.92
Volume 24 ore:
503.20K
Relative Volume:
0.28
Capitalizzazione di mercato:
$105.27B
Reddito:
$11.39B
Utile/perdita netta:
$3.64B
Rapporto P/E:
29.30
EPS:
13.9904
Flusso di cassa netto:
$3.50B
1 W Prestazione:
-1.09%
1M Prestazione:
+4.85%
6M Prestazione:
-15.55%
1 anno Prestazione:
-15.79%
Intervallo 1D:
$406.85
$413.31
Intervallo di 1 settimana:
$402.58
$415.55
Portata 52W:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
410.58 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
485.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.80 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
831.89 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.36 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Will Vertex Pharmaceuticals Incorporated bounce back from current supportJuly 2025 Final Week & Fast Gain Stock Tips - newser.com
Can Vertex Pharmaceuticals Incorporated stock resist sector downturnsWeekly Trade Review & Entry Point Confirmation Signals - newser.com
Custom watchlist performance reports with Vertex Pharmaceuticals IncorporatedJuly 2025 Decliners & Community Consensus Picks - newser.com
2 Unstoppable Growth Stocks to Buy During a Market Crash - The Motley Fool
Best Biotech Stocks To Follow NowOctober 10th - MarketBeat
Lobbying Update: $1,110,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
11 Newly Overvalued Stocks this Week - Morningstar
Griffin Asset Management Inc. Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Analysis: Navigating a Promising 18% Upside in the Biotech Leader - DirectorsTalk Interviews
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsProfit Target & Weekly Market Pulse Alerts - newser.com
Promising Biotech Stocks To Follow NowOctober 11th - MarketBeat
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialJuly 2025 Technicals & AI Powered Buy/Sell Recommendations - newser.com
Apollon Wealth Management LLC Purchases 4,630 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Meritage Portfolio Management Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Vanguard Personalized Indexing Management LLC - MarketBeat
US Bancorp DE Acquires 1,324 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Commerzbank Aktiengesellschaft FI Has $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Galvin Gaustad & Stein LLC - MarketBeat
Aberdeen Group plc Has $128.20 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Callan Family Office LLC - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Blair William & Co. IL - MarketBeat
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News - GuruFocus
Pharma Compliance Trends Revealed at PCC West - BioXconomy
Recovering from injury, Boston Celtics star Jayson Tatum laces up for Vertex campaign - PRWeek
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Quantitative breakdown of Vertex Pharmaceuticals Incorporated recent moveWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Vertex Pharmaceuticals Incorporated stock daily chart insightsJuly 2025 Setups & Risk Managed Investment Signals - newser.com
Trifecta Capital Advisors LLC Buys 802 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Optas LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vontobel Holding Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Weiss Ratings Reiterates "Hold (C+)" Rating for Vertex Pharmaceuticals (NASDAQ:VRTX) - MarketBeat
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market - Yahoo Finance
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Indicators - Markets Mojo
Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025? - Yahoo Finance
RBC Capital Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors - Business Wire
Prime Capital Investment Advisors LLC Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $530.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Vertex’s quest for a breakthrough in Type 1 diabetes - PharmaVoice
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
RBC Raises Price Target on Vertex Pharmaceuticals to $423 From $405, Keeps Sector Perform Rating - MarketScreener
Dohj LLC Purchases Shares of 857 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Smartest Growth Stock to Buy With $500 Right Now - Yahoo Finance
The 5 Most Powerful Women in Biopharma - BioSpace
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Stake Lifted by KLP Kapitalforvaltning AS - MarketBeat
Shell Asset Management Co. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
SteelPeak Wealth LLC Makes New $10.06 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Simplicity Wealth LLC Purchases 1,736 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals a Smart Investment After Recent FDA Approval for Sickle Cell Therapy? - Sahm
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.24%
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):